Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Double-Blind, Dose-Comparison Concurrent Control Study to Assess the Safety and Tolerability of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease

Next Previous
Trial Profile

A Prospective, Randomized, Double-Blind, Dose-Comparison Concurrent Control Study to Assess the Safety and Tolerability of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GRF-6019 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Alkahest

    • Most Recent Events

    • 28 Jan 2021 According an Alkahest media release, Having completed human studies with GRF6019 in patients with both mild-to-moderate and severe Alzheimer's disease, Alkahest plans to advance GRF6019 to further study its efficacy in these patient populations.
    • 28 Jan 2021 Results published in the Alkahest Media Release
    • 28 Jan 2021 According an Alkahest media release, it announced the publication of a peer-reviewed article in the journal Alzheimer's & Dementia: Translational Research & Clinical Interventions. The publication titled, "Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer's disease dementia."
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top